What are the resistance mechanisms of Platinib?

The mechanism of resistance to platinib is a complex and diverse topic involving biological and molecular biological processes at multiple levels.

One of the most common drug resistance mechanisms is secondary mutations of target genes in cancer cells. In platinib treatment, these mutations may change the way the drug binds to its target RET, causing the drug to be less effective or ineffective. For example, specific mutations in the RET gene can render platinib ineffective in inhibiting its activity, allowing cancer cells to continue to proliferate.

Cancer cells may activate alternative signaling pathways that bypass the inhibitory effects of platinib. These alternative pathways may include the activation of other kinases or growth factor pathways, which can compensate for the inhibition of the RET signaling pathway and thereby maintain the survival and proliferation of cancer cells. This mechanism allows cancer cells to continue growing in the presence of platinib.

Certain cancer cells may increase the expression of proteins that pump drugs out of the cell. These proteins, such as members of the ABC transporter family, can expel platinib from cells and reduce its effective intracellular concentration, leading to drug resistance. This mechanism is one of the common strategies used by cancer cells to become resistant to multiple drugs.

A rare but important mechanism of resistance is histological transformation of tumors. For example, patients with RET rearranged lung adenocarcinoma may transform into small cell lung cancer (SCLC) after treatment. This transformation changes the biology of the tumors, making tumors that were originally sensitive to platinib no longer responsive. This transformation may involve mutations in key genes such as TP53 and RB1, which play an important role in the occurrence and development of SCLC.

In addition to the above mechanisms, there are also amplification of the MET gene, TP53 mutations, and other rare sites such as CTNNB1Point mutations may be involved in the resistance process of platinib. These changes may act alone or together to make cancer cells less sensitive to drugs.